Discontinuation Study
Phase NA Recruiting
70 enrolled
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
Phase 1/2 Recruiting
130 enrolled
Collection of Tissue Samples for Cancer Research
Recruiting
5,000 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib
Phase 1/2 Recruiting
440 enrolled
TAPUR
Phase 2 Recruiting
4,200 enrolled
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Phase 1 Recruiting
210 enrolled
SURGE
Phase NA Recruiting
300 enrolled
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
Phase NA Recruiting
40 enrolled
Plan Development for Giving Teclistamab in the Outpatient Setting
Phase 4 Recruiting
15 enrolled
POSBIO-CRC
Phase NA Recruiting
164 enrolled
DETERMINE
Phase 2/3 Recruiting
30 enrolled
e-Motion : Promoting Emotion Regulation in Chronic Cancer
Phase NA Recruiting
30 enrolled
VRd MM Fibrate
Phase 4 Recruiting
44 enrolled
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Recruiting
15,000 enrolled
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
Phase 2/3 Recruiting
900 enrolled
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
Phase 2/3 Recruiting
900 enrolled
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)
Phase 2/3 Recruiting
900 enrolled
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Phase 2 Recruiting
50 enrolled
inMMyCAR
Phase 1 Recruiting
40 enrolled
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
Phase NA Recruiting
120 enrolled
CARLOTTA01
Phase 1 Recruiting
16 enrolled
CARTIER
Phase NA Recruiting
514 enrolled
AmbuSpé
Recruiting
40 enrolled
Survivorship
Recruiting
45 enrolled
BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
Phase 1/2 Recruiting
10 enrolled
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting
20,000 enrolled
RATIONALISE
Phase 2/3 Recruiting
300 enrolled
CER
Recruiting
15,000 enrolled
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Phase 1/2 Recruiting
36 enrolled